Mustang Bio (NASDAQ:MBIO) Releases Quarterly Earnings Results, Beats Estimates By $139.86 EPS
by Teresa Graham · The Cerbat GemMustang Bio (NASDAQ:MBIO – Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($140.00) by $139.86, FiscalAI reports.
Mustang Bio Stock Up 2.9%
Shares of MBIO stock traded up $0.02 on Tuesday, hitting $0.77. The company had a trading volume of 57,280 shares, compared to its average volume of 38,775. The firm has a market cap of $5.87 million, a P/E ratio of -1.98 and a beta of 2.11. The company has a 50-day moving average price of $0.83 and a 200-day moving average price of $1.03. Mustang Bio has a twelve month low of $0.53 and a twelve month high of $7.00.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Mustang Bio in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Mustang Bio presently has a consensus rating of “Sell”.
Check Out Our Latest Report on MBIO
Hedge Funds Weigh In On Mustang Bio
An institutional investor recently bought a new position in Mustang Bio stock. DRW Securities LLC purchased a new position in Mustang Bio, Inc. (NASDAQ:MBIO – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 73,936 shares of the company’s stock, valued at approximately $73,000. DRW Securities LLC owned 1.01% of Mustang Bio at the end of the most recent quarter. 9.95% of the stock is owned by institutional investors and hedge funds.
Mustang Bio Company Profile
Mustang Bio, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cell and gene therapies for oncology and rare genetic diseases. The company’s primary platform leverages chimeric antigen receptor T‐cell (CAR-T) technology to target both hematologic and solid tumor indications. In parallel, Mustang Bio is advancing a portfolio of lentiviral‐based gene therapy candidates designed to address inherited metabolic disorders with high unmet medical need.
The company’s oncology pipeline includes programs directed at B-cell malignancies and aggressive brain tumors, with lead CAR-T candidates in clinical trials for glioblastoma multiforme and various B-cell leukemias and lymphomas.